$STE

Sohi Mohsen sold $957K of STE

Sohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.

Original reporting
SEC EDGAR · Sohi Mohsen
Published Aug 12, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by a director on 2026-08-12.

02

Market read

A director’s open-market sale is disclosed, but there is no accompanying operational, financial, or regulatory catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, trading impact is usually limited.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

STERIS director Sohi Mohsen filed a Form 4 selling 4,058 shares at $235.7800 on 2026-08-12 for about $956,795.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no accompanying company news, guidance, or transaction context beyond the sale details.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

Absence of a disclosed 10b5-1 plan could be interpreted as less mechanical selling, but the article still lacks any linkage to company fundamentals.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Sohi Mohsen

    Director who sold 4,058 shares on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEHighAI 8/10

STERIS Stock Outlook: Is Wall Street Bullish or Bearish?

STERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.

$STEMed

STERIS Q1 Earnings Call Highlights

STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.

$STEMed

STERIS plc (STE): Results of Operations and Financial Condition

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share i

$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.